Ocugen Statistics
Total Valuation
Ocugen has a market cap or net worth of $471.36 million. The enterprise value is $459.30 million.
| Market Cap | 471.36M |
| Enterprise Value | 459.30M |
Important Dates
The last earnings date was Thursday, August 6, 2026, before market open.
| Earnings Date | Aug 6, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Ocugen has 339.11 million shares outstanding. The number of shares has increased by 11.22% in one year.
| Current Share Class | 339.11M |
| Shares Outstanding | 339.11M |
| Shares Change (YoY) | +11.22% |
| Shares Change (QoQ) | +3.40% |
| Owned by Insiders (%) | 1.69% |
| Owned by Institutions (%) | 42.92% |
| Float | 333.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 102.90 |
| Forward PS | 387.13 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 100.26 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.80
| Current Ratio | 0.80 |
| Quick Ratio | 0.75 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -8.16 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -48.44% |
| Return on Invested Capital (ROIC) | -80.26% |
| Return on Capital Employed (ROCE) | 776.45% |
| Weighted Average Cost of Capital (WACC) | 14.98% |
| Revenue Per Employee | $39,491 |
| Profits Per Employee | -$705,267 |
| Employee Count | 116 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +37.62% in the last 52 weeks. The beta is 2.20, so Ocugen's price volatility has been higher than the market average.
| Beta (5Y) | 2.20 |
| 52-Week Price Change | +37.62% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 1.51 |
| Relative Strength Index (RSI) | 53.72 |
| Average Volume (20 Days) | 4,283,714 |
Short Selling Information
The latest short interest is 100.91 million, so 29.76% of the outstanding shares have been sold short.
| Short Interest | 100.91M |
| Short Previous Month | 100.59M |
| Short % of Shares Out | 29.76% |
| Short % of Float | 30.27% |
| Short Ratio (days to cover) | 19.10 |
Income Statement
In the last 12 months, Ocugen had revenue of $4.58 million and -$81.81 million in losses. Loss per share was -$0.26.
| Revenue | 4.58M |
| Gross Profit | -39.18M |
| Operating Income | -68.90M |
| Pretax Income | -81.81M |
| Net Income | -81.81M |
| EBITDA | -67.17M |
| EBIT | -68.90M |
| Loss Per Share | -$0.26 |
Balance Sheet
The company has $100.05 million in cash and $87.99 million in debt, with a net cash position of $12.07 million or $0.04 per share.
| Cash & Cash Equivalents | 100.05M |
| Total Debt | 87.99M |
| Net Cash | 12.07M |
| Net Cash Per Share | $0.04 |
| Equity (Book Value) | -16.56M |
| Book Value Per Share | -0.05 |
| Working Capital | -26.36M |
Cash Flow
In the last 12 months, operating cash flow was -$60.87 million and capital expenditures -$153,000, giving a free cash flow of -$61.02 million.
| Operating Cash Flow | -60.87M |
| Capital Expenditures | -153,000 |
| Depreciation & Amortization | 1.73M |
| Net Borrowing | 84.26M |
| Free Cash Flow | -61.02M |
| FCF Per Share | -$0.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,504.08% |
| Pretax Margin | -1,785.88% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Ocugen does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.22% |
| Shareholder Yield | -11.22% |
| Earnings Yield | -17.36% |
| FCF Yield | -12.95% |
Analyst Forecast
The average price target for Ocugen is $12.17, which is 775.54% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $12.17 |
| Price Target Difference | 775.54% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 261.90% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Ocugen has an Altman Z-Score of -5.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.17 |
| Piotroski F-Score | 2 |